Unique ID issued by UMIN | UMIN000029921 |
---|---|
Receipt number | R000034183 |
Scientific Title | Study of effects on the retina and the choroid of intravitreal ranibizmab injection in patients with macular edema due to central retinal vein occlusion. |
Date of disclosure of the study information | 2017/11/10 |
Last modified on | 2018/11/12 08:57:49 |
Study of effects on the retina and the choroid of intravitreal ranibizmab injection in patients with macular edema due to central retinal vein occlusion.
Study of effects of Ranibizmab in patients with macular edema due to central retinal vein occlusion.
Study of effects on the retina and the choroid of intravitreal ranibizmab injection in patients with macular edema due to central retinal vein occlusion.
Study of effects of Ranibizmab in patients with macular edema due to central retinal vein occlusion.
Japan |
central retinal vein occlusion
Ophthalmology |
Others
NO
Ranibizmab intravitreal injection, central retinal thickness, foveal choroidal thickness, retinal and choroidal blood flow to observe the effect on the change
Efficacy
The improvement rate of best corrected visual acuity at three months after the Ranibizmab injection.
1-3.The changes of best corrected visual acuity, central retinal thickness, foveal choroidal thickness by OCT, retinal and choroidal blood flow changes by LSFG at 1 and 3 months after the Ranibizmab injection.
4.Duration from Ranobizmab injection to recurrence.
5.Adverse event
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Intravitreal administration of Ranibizmab(Lucentis)
20 | years-old | <= |
Not applicable |
Male and Female
1.Patients with macular edema due to central retinal vein occlusion.
2.Central retinal thickness-=>250µm
3.Point visual acuity less than 0.9
4.Age of patients 20years of age or older at the time of acquisition agreement.
5.After receiving a sufficient explanation upon participation in this study,on a full understanding,patients who obtained the document voluntary consent of the patient himself
1.Patients who underwent the pan-retinal photocoagulation within 3 months.
2.Patients who underwent photocoagulation treatment for macular edema within 3 months.
3.Patients treated with steroids to intraocular within 3 months.
4.Patients who underwent anti-VEGF injection for macular edema within 3 months.
3.Patients treated with steroids to intraocular within 3 months.
5.The patients with a history of hypersensitivity to the study drug.
6.Patients who developed heart and cerebrovascular disease severe within 6 months.
7.Patients attending physician was deemed inappropriate as a subject.
30
1st name | |
Middle name | |
Last name | Takashi Kitaoka |
Nagasaki University Hospital
Ophthalmology
1-7-1 Sakamoto,Nagasaki
095-819-7345
tkitaoka@nagasaki-u.ac.jp
1st name | |
Middle name | |
Last name | EIKO TSUIKI |
Nagasaki University Hospital
Ophthalmology
1-7-1 Sakamoto,Nagasaki
095-819-7345
t-eiko@nagasaki-u.ac.jp
Nagasaki University Hospital
none
Self funding
NO
2017 | Year | 11 | Month | 10 | Day |
Partially published
No longer recruiting
2013 | Year | 10 | Month | 13 | Day |
2014 | Year | 01 | Month | 01 | Day |
2017 | Year | 12 | Month | 31 | Day |
2017 | Year | 12 | Month | 31 | Day |
2017 | Year | 12 | Month | 31 | Day |
2018 | Year | 12 | Month | 31 | Day |
2017 | Year | 11 | Month | 10 | Day |
2018 | Year | 11 | Month | 12 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034183